Exploitable mechanisms for the blockade of androgenic action.
Griffiths
K
K
Tenovus Cancer Research Centre, University of Wales College of Medicine, Cardiff, Wales, UK.
Denis
L J
LJ
D000726:Androgen Antagonists / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use; D018120:Finasteride / Q000627:therapeutic use; D005544:Forecasting; D006801:Humans; D007425:Intracellular Membranes / Q000502:physiology; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000502:physiology
D000726:Androgen Antagonists; D004791:Enzyme Inhibitors; D004967:Estrogens; D018120:Finasteride; D011505:Protein-Tyrosine Kinases